Savara inc. appoints badrul chowdhury as chief medical officer

Savara inc. announced the appointment of badrul chowdhury to the newly created position of chief medical officer, effective immediately. dr. chowdhury will be savara’s senior physician overseeing the medical and regulatory strategy of the company’s investigational programs from late-stage development through to approval. he will also provide oversight of medical affairs and patient safety across the portfolio. dr. chowdhury joins savara from astrazeneca, where he was senior vice president, chief physician-scientist for respiratory, inflammation, and autoimmunity late stage development, in biopharmaceuticals r&d. for 16 years prior to that, dr. chowdhury served as director, division of pulmonary, allergy, and rheumatology products, center for drug evaluation and research (cder) at the u.s. food and drug administration where he provided scientific and regulatory oversight of both common and rare diseases such as asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, rheumatoid arthritis, systemic lupus erythromatosis, and various autoimmune and inflammatory diseases. dr. chowdhury has been a member of many committees within the fda, nih, world health organization (who), united nations environmental programme (unep), and the american academy of allergy, asthma, and immunology (aaaai). additionally, he has published scientific articles in more than 60 peer-reviewed scientific and medical journals and has been bestowed numerous research, academic, and service awards/honors.
SVRA Ratings Summary
SVRA Quant Ranking